Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

ANCA-Associated Vasculitis in Systemic Sclerosis

Carmen Busca Arenzana, MR, Ander Mayor-Ibarguren, MR, Amara Pieren-Salazar, MR, Natalia Martin-Suñe, MD, Isabel Esteban-Rodríguez, MD, Juan José Ríos-Blanco, MD, & Francisco Arnalich-Fernández, MD  |  Issue: October 2014  |  October 1, 2014

Muscle & Peripheral Nerve Disease?Muscle & Peripheral Nerve Disease?
Figures: Muscle biopsy (hematoxylin-eosin), which shows striated muscle with necrotizing vasculitis (microscopic polyangiitis) and signs of denervation.

Patients with diffuse systemic sclerosis (dSS) with an associated ANCA-positive vasculitis have been infrequently described. In this article, we report the case of a 53-year-old woman, previously diagnosed with dSS, who developed an ANCA-associated vasculitis, which manifest as peripheral nerve and muscle disease.

Scleroderma is a disease characterized by sclerosis of the skin and visceral organs, vasculopathy, Raynaud’s phenomenon and the presence of autoantibodies. The disease spectrum is wide, with systemic and localized forms, depending on the extent of skin thickening. There is also a vasculopathy involving multiple organ systems that leads to the presence of cutaneous and mucosal telangiectasias, digital ulcers and tissue ischemia. Medium-size vessels can also be involved, sometimes leading to scleroderma renal crisis or pulmonary artery hypertension. However, scleroderma is rarely associated with an ANCA-positive vasculitis. We report this unique situation.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Case Report

A 53-year-old woman was admitted to our hospital with weakness and numbness in her legs. She had been diagnosed with Raynaud’s phenomenon 10 years before, followed by the development of autoimmune hypothyroidism. Three years later, she complained of telangiectasias spreading over her face and neck, and she developed a digital ulcer on her middle finger. She noted a dry cough and dyspnea on exertion. The ANA and the anti-topoisomerase antibodies (Scl-70) were positive. She was diagnosed with dSS with pulmonary involvement (moderate to severe pulmonary fibrosis).

There was no evidence for pulmonary hypertension, or cardiac or esophageal involvement. After being treated for a presumed episode of pneumonia, she failed to significantly improve, and her cough and dyspnea worsened. She complained of weakness and numbness in her distal lower extremities with preserved muscle strength and hypoesthesia to touch.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The development of vasculitis in patients with systemic sclerosis is highly uncommon.

Initial laboratory tests included a normocytic and normochromic anemia, thrombocytosis, elevated acute-phase reactants and normal serum creatinine. MPO-ANCA titer was 174 AU (normal <10 UI/mL). PR-3-ANCA was negative. Antiglomerular basal membrane and anti-Jo-1 antibodies were negative, and complement C3 and C4 were within normal limits. An electromyogram showed evidence of a moderate myopathy without polyneuropathy or myositis. A muscle and peripheral nerve biopsy demonstrated features of a necrotizing vasculitis with signs of axonal degeneration and severe denervation attributable to ischemic neuropathy (see figures, right).

Therapy was initiated with a high dose of prednisolone (bolus of 1 mg/kg/day IV for three days, followed by 60 mg PO daily) and cyclophosphamide treatment (five monthly IV boluses of 750 mg each) was initiated. A few weeks later, maintenance immunosuppressive therapy was introduced with azathioprine (150 mg day PO), and her hypoesthesia and weakness gradually disappeared.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsSystemic Sclerosis Tagged with:ANCA-Associated Vasculitisdrugpatient careprednisoneRaynaud'srheumatologistSclerodermaSystemic sclerosisTreatmentVasculitis

Related Articles

    New Tools for Myositis Diagnosis, Classification & Management

    April 15, 2019

    CHICAGO—At Hot Topics in Myositis, a session at the 2018 ACR/ARHP Annual Meeting, three experts discussed new classification criteria for idiopathic inflammatory myopathies (IIM) and offered practical primers on overlap myositis conditions and inclusion body myositis (IBM). New Myositis Classification Criteria After a 10-year development process, the new EULAR/ACR Classification Criteria for Adult and Juvenile…

    Case Report: Hydralazine-Induced ANCA-Associated Vasculitis

    February 16, 2021

    Hydralazine has been in use as a treatment for hypertension, most notably in heart failure patients, since 1951.1 The drug is a known cause of autoimmune disease, most specifically hydralazine-induced lupus.  Hydralazine-induced lupus occurs in 7–13% of those taking the medication.2-4 It often presents with constitutional symptoms, arthritis/arthralgias, cutaneous lesions, sero­sitis, myalgias and/or hepatomegaly. Features…

    Lost and found

    The History of ACE Inhibitors in Scleroderma Renal Crisis

    February 16, 2021

    Scleroderma renal crisis is a true medical emergency in rheumatology, one that requires prompt diagnosis and treatment. Here, we review the historic introduction of the angiotensin-converting enzyme inhibitors in this context, and highlight management and key questions moving forward. Background Awareness of renal disease in scleroderma dates back many years. The revered physician William Osler…

    Case Report: Interstitial Lung Disease with Positive ANCA Test

    October 13, 2015

    “Worst of all is the pain in my calves,” she said. “It feels like burning deep inside.” So began my first encounter with a 69-year-old woman who was referred to rheumatology clinic for evaluation of two months of constitutional symptoms and a positive ANCA test, which had been ordered by her primary care doctor. Her…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences